A Phase 2 randomized, open-label trial to evaluate the safety, tolerability, PK, and antitumor activity of immunotherapy-based treatment combinations in participants with metastatic colorectal cancer who are refractory to first- and second-line therapies. Participants will be assigned to one of several treatment arms, including regorafenib + atezolizumab ± etrumadenant.
Key Eligibility Criteria
- Histologically confirmed adenocarcinoma originating from the colon or rectum
- Metastatic disease not amenable to local treatment
- Disease progression during or following not more than 2 separate lines of treatment for metastatic colorectal cancer that consisted of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy in combination with a biologic agent
- No prior treatment with T cell co-stimulating or immune checkpoint blockade therapies including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies